Stock Market Today, Jan. 23: ImmunityBio Falls After Gaining Over 200% in a Month

Impact · against what's priced in

ImmunityBio (IBRX) is seeing a significant valuation re-rating driven by a shift to profitability and expanded indications for Anktiva, though recent price action suggests some profit-taking after a 200% monthly rally. The news is highly material for IBRX, while Merck and BioNTech remain largely unaffected by the noise.

IBRX+0.70: No priced-in read yet

Stock Market Today, Jan. 23: ImmunityBio Falls After Gaining Over 200% in a Month

What matters in this story

Harrow's Top Two Drugs Alone Can Justify Its Current Valuation

Stock Market Today, Jan. 23: ImmunityBio Falls After Gaining Over 200% in a Month

What matters in this story

Harrow's Top Two Drugs Alone Can Justify Its Current Valuation

How each ticker is affected

Connected tickers

Track these names every morning.

GSK: The Gas Pedal Is Still Down, But Bumps Ahead

LIN Q3 Earnings Beat Estimates on Higher Americas Pricing & Volumes

Baxter Q3 Earnings Beat on Broad-Based Growth, '26 Outlook Raised

Eli Lilly: Mounjaro And Zepbound Keep The Growth Story Alive

Stock Market Today, Jan. 23: ImmunityBio Falls After Gaining Over 200% in a Month

What matters in this story

Next reads from the same story arc

Harrow's Top Two Drugs Alone Can Justify Its Current Valuation

Stock Market Today, Jan. 23: ImmunityBio Falls After Gaining Over 200% in a Month

What matters in this story

Next reads from the same story arc

Harrow's Top Two Drugs Alone Can Justify Its Current Valuation

How each ticker is affected

Connected tickers

Track these names every morning.

GSK: The Gas Pedal Is Still Down, But Bumps Ahead

LIN Q3 Earnings Beat Estimates on Higher Americas Pricing & Volumes

Baxter Q3 Earnings Beat on Broad-Based Growth, '26 Outlook Raised

Eli Lilly: Mounjaro And Zepbound Keep The Growth Story Alive